This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Flu vaccine - adjuvant IC31
Drug Names(s): Flu vaccine - adjuvant IC31
Description: Intercell's Flu vaccine is a seasonal influenza vaccine which is formulated with Intercell's adjuvant IC31. Adjuvants enhance the effectiveness of vaccines. IC31 is an adjuvant inducing both T-cell and B-cell responses with a unique syntheticformulation, which combines the immunostimulating properties of an anti-microbial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two-component solution can simply be mixed with antigens: no conjugation is required.
In July 2007, Intercell and Novartis announced that they agreed to form a major strategic partnership to accelerate innovation in vaccines development in infectious diseases. Intercells adjuvant IC31 will be exclusively licensed to Novartis for the development of improved Influenza vaccines. IC31 will also be non-exclusively licensed to Novartis in other areas. Intercell retains the right to continue to enter into partnerships for IC31 with third parties in infectious diseases, cancer, allergies, and other indications.
In May 2013, Valneva announced its creation through the completion of the merger of equals between Vivalis and Intercell.
Novartis and CSL
In October 2014, Novartis entered into a definitive agreement to divest its influenza vaccines business to CSL Limited (CSL) for an agreed price of USD 275 million. This transaction requires regulatory approvals and is expected to close in the second half of 2015.
In August 2015, CSL announced that...See full deal structure in Biomedtracker
Partners: Valneva SE
Flu vaccine - adjuvant IC31 News
Additional information available to subscribers only: